NetworkNewsBreaks – Earth Science Tech, Inc. (ET
Post# of 333
(Total Views: 244)
Posted On: 04/23/2018 3:59:53 PM
NetworkNewsBreaks – Earth Science Tech, Inc. (ETST) Employs Proactive Approach to Accelerate Development Growth
Innovative biotech company Earth Science Tech (OTC: ETST), through its partnership with Laboratories BNK Canada, Inc., is advancing toward commercialization of its new testing services. An article discussing the company reads: “Through ETST’s connection with Défi Montréal, key individuals have already been brought on board to advance the acceleration of operations. In January 2018, ETST announced a deal with Laboratories BNK Canada, Inc. for clinical studies related to the MSN-2 medical device. The MSN-2 is a home kit designed for the detection of sexually transmitted infections (STIs) from a self-obtained gynecological specimen. MSN-2 has been confirmed through studies to detect chlamydia. The company is working to validate similar results for gonorrhea. Testing for trichomoniasis, as well as different serotypes of the human papillomavirus (HPV), are expected to be added in the near future. Partnering with Laboratories BNK offers ETST an accelerated plan of development for more products while cutting costs and, ideally, treating more patients. This arrangement gives ETST the means to accelerate the commercialization of its new testing services while it works toward its ultimate goal of halting the spread of STIs.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Innovative biotech company Earth Science Tech (OTC: ETST), through its partnership with Laboratories BNK Canada, Inc., is advancing toward commercialization of its new testing services. An article discussing the company reads: “Through ETST’s connection with Défi Montréal, key individuals have already been brought on board to advance the acceleration of operations. In January 2018, ETST announced a deal with Laboratories BNK Canada, Inc. for clinical studies related to the MSN-2 medical device. The MSN-2 is a home kit designed for the detection of sexually transmitted infections (STIs) from a self-obtained gynecological specimen. MSN-2 has been confirmed through studies to detect chlamydia. The company is working to validate similar results for gonorrhea. Testing for trichomoniasis, as well as different serotypes of the human papillomavirus (HPV), are expected to be added in the near future. Partnering with Laboratories BNK offers ETST an accelerated plan of development for more products while cutting costs and, ideally, treating more patients. This arrangement gives ETST the means to accelerate the commercialization of its new testing services while it works toward its ultimate goal of halting the spread of STIs.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)